Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.49 |
| ▸ | ACLY | P53396 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.44 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.43 |
| ▸ | FLT1 | P17948 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29836060 | 1.00 | MAPK1 (0.52) | MAPK1TSHRVCAM1ACLYCYP1A2 | |
| Ammonia Solution, Strong SCHEMBL28325235 | 0.98 | MAPK1 (0.50) | MAPK1TSHRVCAM1ACLYCYP1A2 | |
| SCHEMBL358223 | 0.88 | ACLY (0.52) | MAPK1TSHRVCAM1ACLYCYP1A2 | |
| SCHEMBL67536 | 0.87 | MAPK1 (0.53) | MAPK1TSHRVCAM1ACLYCYP1A2 | |
| SCHEMBL67686 | 0.85 | ALDH1A1 (0.58) | MAPK1TSHRVCAM1ACLYCYP1A2 | |
| SCHEMBL535249 | 0.84 | MAPK1 (0.53) | MAPK1TSHRVCAM1ACLYCYP1A2 | |
| SCHEMBL5149992 | 0.82 | MAPK1 (0.52) | MAPK1TSHRVCAM1ACLYCYP1A2 | |
| SCHEMBL5740032 | 0.82 | MAPK1 (0.52) | MAPK1TSHRVCAM1ACLYCYP1A2 | |
| SCHEMBL536046 | 0.82 | ACLY (0.42) | MAPK1TSHRVCAM1ACLYCYP1A2 | |
| SCHEMBL357928 | 0.81 | PDK1 (0.55) | MAPK1TSHRVCAM1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118059916-A | Pt/NiZnFe-LDH@C3N4Catalyst, preparation method and application thereof | 南京工业大学 | 2024-05-24 | — | — | CN | disclosed |
| CN-115010646-B | Photoinduction synthesis method of indolone compound | 南京大学 | 2024-02-06 | — | — | CN | disclosed |
| CN-115010646-A | Photoinduction synthesis method of indolone compounds | 南京大学 | 2022-09-06 | — | — | CN | disclosed |
| US-20160207938-A1 | QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2016-07-21 | — | — | US | disclosed |
| US-9273013-B2 | Quinazoline derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-01 | — | — | US | disclosed |
| US-20130178624-A1 | QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-07-11 | — | — | US | disclosed |
| US-8394786-B2 | Quinazoline derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-03-12 | — | — | US | disclosed |
| CN-102718775-A | Macrocyclic quinazoline derivatives as antiproliferative agents | JANSSEN PHARMACEUTICA NV | 2012-10-10 | — | — | CN | disclosed |
| EP-1633365-B1 | MACROCYCLIC QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2012-02-08 | — | — | EP | disclosed |
| EP-2305687-A1 | Quinazoline derivatives | Janssen Pharmaceutica NV (BE) | 2011-04-06 | — | — | EP | disclosed |
| US-20040034005-A1 | [1,4]Diazocino[7,8,1-hi]indole derivatives as antipsychotic and antiobesity agents | WYETH | 2004-02-19 | — | — | US | disclosed |
| WO-2003091257-A1 | [1,4]DIAZOCINO [7,8,1-hi]INDOLE DERIVATIVES AS ANTIPSYCHOTIC AND ANTIOBESITY AGENTS | WYETH (US) | 2003-11-06 | — | — | WO | disclosed |
| EP-0797580-B1 | NUCLEOSIDE DERIVATIVES WITH PHOTOLABILE PROTECTIVE GROUPS | PFLEIDERER WOLFGANG (DE) | 2002-04-10 | — | — | EP | disclosed |
| EP-0901501-B1 | NUCLEOSIDE DERIVATIVES WITH PHOTO-UNSTABLE PROTECTIVE GROUPS | PFLEIDERER WOLFGANG (DE) | 2001-10-17 | — | — | EP | disclosed |
| US-6153744-A | LIGHT-CONTROLLED SYNTHESIS OF OLIGONUCLEOTIDES ON A DNA CHIP | WOLFGANG PFLEIDERER (DE) | 2000-11-28 | — | — | US | disclosed |
| EP-0901501-A1 | NUCLEOSIDE DERIVATIVES WITH PHOTO-UNSTABLE PROTECTIVE GROUPS | Pfleiderer, Wolfgang (DE) | 1999-03-17 | — | — | EP | disclosed |
| US-5763599-A | FOR LIGHT-CONTROLLED SYNTHESIS OF OLIGONUCLEOTIDES ON DNA CHIP | Pfleiderer, Wolfgang (DE) | 1998-06-09 | — | — | US | disclosed |
| WO-1997044345-A1 | NUCLEOSIDE DERIVATIVES WITH PHOTO-UNSTABLE PROTECTIVE GROUPS | PFLEIDERER WOLFGANG (DE) | 1997-11-27 | — | — | WO | disclosed |
| EP-0797580-A2 | NUCLEOSIDE DERIVATIVES WITH PHOTOLABILE PROTECTIVE GROUPS | Pfleiderer, Wolfgang (DE) | 1997-10-01 | — | — | EP | disclosed |
| WO-1996018634-A2 | NUCLEOSIDE DERIVATIVES WITH PHOTOLABILE PROTECTIVE GROUPS | PFLEIDERER WOLFGANG (DE) | 1996-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178624-A1 | QUINAZOLINE DERIVATIVES | NR1H2, NR1H3, NR3C2 | MAPK1 3902/4885TSHR 496/4885VCAM1 4576/4885 |
| US-20160207938-A1 | QUINAZOLINE DERIVATIVES | NR1H2, NR1H3, NR3C2 | MAPK1 4018/4885TSHR 362/4885VCAM1 4741/4885 |
| US-20040034005-A1 | [1,4]Diazocino[7,8,1-hi]indole derivatives as antipsychotic and antiobesity agents | HTR1A, HTR2C, HTR1D | MAPK1 997/4885TSHR 259/4885VCAM1 3541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.